Sign in
CompletedNo phase

PLASOMA Ultimate Safety & Efficacy Study

Key facts

Who runs it
Plasmacure
Where
Netherlands6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
101 people enrolled
Started
26 May 2021
Ended
16 Dec 2024
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • PLASOMA
Record updated
3 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • INCL1: have a slow-healing or non-healing ulcer consisting of, but not limited to:
  • diabetic ulcers (Wagner-Meggitt classification system/ University of Texas classification system: grades 1-3)
  • venous ulcers
  • pressure ulcers (international NPUAP/EPUAP classification system: categories/stages II-IV)
  • burn wounds (second and third degree)
  • skin grafts and flaps
  • infected post-surgical ulcers. Standard wound care has not resulted in sufficient healing after at least two weeks (including first line care) (Ref 25, Ref 26); Note: There is no upper limit for the duration that the wound exists. In case a subject has multiple wounds that meet the in- and exclusion criteria, the wound with the longest duration will be chosen for the study; INCL2: have a wound with a minimum wound surface area of 0.5 cm2 and a maximum diameter of 4.5 cm (~16 cm2 wound surface area for circular wounds); INCL3: have a minimum age of 18 years old; INCL4: for home care treatments only: have a grounded wall socket available for connection of PLASOMA

Who cannot take part

  • a metal implant (including a stent) is present in the treatment area, i.e. the area between pad and electrode
  • the to-be-treated wound is located on the torso above the navel; EXCL2: the subject has any known malignant wound degeneration; EXCL3: the subject receives treatment with immunosuppressive agents or oral corticosteroids; no exclusion if subject has received a stable dose for at least 2 months and the oral corticosteroid dose does not exceed 7.5 mg/day prednisone or equivalent; EXCL4: the subject is receiving or likely to receive advanced wound therapies - such as negative pressure therapy, hyperbaric oxygen therapy, biologicals (e.g. skin substitutes, growth factors), electrophysical therapy - until FU1 for the to be-treated wound. Advanced wound dressings are not excluded; EXCL5: the subject participates in another study which is likely to compromise the outcome of the PULSE study or the feasibility of the subject fulfilling the PULSE study; EXCL6: the subject is unable to provide consent
  • a conductive connection from outside to inside the body at or near the heart is present, e.g. a catheter with electrolyte fluid
  • the subject has epilepsy
  • an electronic medical device is attached to the body, including electronic life support equipment, hearing aids, glucose sensors and insulin pumps. If the sole purpose of the medical device is monitoring, the subject is not excluded, but it should be noted that use of PLASOMA together with such devices has not been tested and may lead to erroneous operation of the attached device during PLASOMA treatment
  • EXCL1: the subject has one or more of the following contraindications for PLASOMA:
  • the wound is very exudative, i.e. wounds in which moisture is visible again within a few minutes after patting dry
  • any implanted active electronic device, such as a pacemaker, is present
  • Note: no exclusion if electronic medical device will be detached during PLASOMA treatment
  • the subject is pregnant

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of the PULSE study are the followingL

Read full original descriptionShow less

A.To perform post market clinical follow up (PMCF) on safety and efficacy:

1. Safety: To confirm transient short-terms side effects and verify long-term/outstanding risks. 2. Efficacy: To confirm the performance of PLASOMA, i.e. the beneficial effect on bacterial load. B. Determine the effect of PLASOMA on wound surface area.

A secondary purpose is to examine the beneficial effects of PLASOMA on wound healing and to perform a health technology assessment (HTA).

This clinical study will be an open label two-armed randomized controlled trial (RCT), performed at at least three sites (multi-center) in the Netherlands.

The two arms are:

1. Control group: Standard wound care for 12 weeks or until healing, whichever occurs first; 2. Treatment group: Standard wound care + PLASOMA treatment for 12 weeks or until healing, whichever occurs first.

The frequency of PLASOMA treatment will be determined by the treating (para)medical professional based on the number of visits they would schedule for the standard wound care at the study site.

For all study subjects, the treatment frequency will be at least once per week (in order to have enough treatments for safety evaluation) and should not exceed once per day.

Follow up (FU) will be performed at three timepoints for both arms:

* FU1: 2 weeks after end treatment period * FU2: 12 weeks after end treatment period * FU3: 12 months after start treatment.

The 2 groups in the trial

  • control groupNo study treatment, for comparison

    Standard of care

  • treatment groupTreatment being tested

    Standard of care + PLASOMA treatment

    Treatment: PLASOMA

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
3 June 2025